Table 3.

Cox regression analysis of factors associated with progression-free survival in the two groups

	Univariate analysis		Multivariate analysis
	HR(95%CI)	P value	HR(95%CI)	P value
FL group (N = 77)
Age (< 58 vs. ≥ 58)	0.730(0.381–1.398)	0.342
Dosage (mg/kg) (7.5 vs. 15)	0.598(0.300–1.193)	0.145
Complete resection (Yes vs. No)	1.782(0.902–3.520)	0.096	1.949(0.915–4.155)	0.084
Bevacizumab-primary vs. bevacizumab-secondary	1.216(0.625–2.366)	0.564
Therapy pattern	0.855(0.563–1.298)	0.462
RT group (N = 78)
Age (< 58 vs. ≥ 58)	0.748(0.450–1.243)	0.262
Platinum sensitivity (sensitive vs. resistant)	4.080(2.307–7.218)	< 0.001	4.234(2.217–8.084)	< 0.001
Previous lines of chemotherapy (< 3 vs. ≥ 3)	1.426(0.836–2.435)	0.193
Dosage (mg/kg) (7.5 vs. 15)	0.778(0.419–1.442)	0.425